- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05593224
The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Intracranial Atherosclerotic Stenosis
October 20, 2022 updated by: Zhuhai Tonbridge Medical Tech. Co., Ltd.
The Efficacy and Safety of the Intracranial Stent (Tonbridge) in Endovascular Treatment of Intracranial Atherosclerotic Stenosis: A Prospective, Multicenter, Single-Arm Trial
The purpose of this study is to verify the efficacy and safety of the Intracranial Stent (Tonbridge) in endovascular treatment of intracranial atherosclerotic stenosis.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, multicenter, single-arm clinical trial carried out in 14 centers throughout China.
156 subjects with intracranial atherosclerotic stenosis will be treated with the Intracranial Stent (Tonbridge) for the expansion of vascular stenosis site.
The primary objective of this study is to evaluate the effectiveness and safety of the intracranial stent for endovascular treatment of intracranial atherosclerotic stenosis.
Study Type
Interventional
Enrollment (Anticipated)
156
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Long Chen
- Phone Number: 13868091267
- Email: long.chen@ton-bridge.com
Study Contact Backup
- Name: Yuhan Yan
- Phone Number: 15843291055
- Email: yh.yan@ton-bridge.com
Study Locations
-
-
-
Shanghai, China
- Changhai Hospital of Shanghai
-
Principal Investigator:
- Jianmin Liu
-
Shanghai, China
- Tongji Hospitai of Tongji University
-
Principal Investigator:
- Chun Fang
-
-
Hebei
-
Shijiazhuang, Hebei, China
- The First Hospital of Hebei Medical University
-
Principal Investigator:
- Conghui Li
-
-
Henan
-
Luoyang, Henan, China
- The First Affiliated Hospital of Henan Science & Technology University
-
Principal Investigator:
- Jisheng Qi
-
-
Hubei
-
Wuhan, Hubei, China
- Zhongnan Hospital of Wuhan University
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Nanjing Drum Tower hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, China
- Jiangxi Provincial People's Hospital
-
Principal Investigator:
- Wenfeng Cao
-
-
Jilin
-
Changchun, Jilin, China
- The First Hospital of Jilin University
-
Principal Investigator:
- Shouchun Wang
-
-
Liaoning
-
Dalian, Liaoning, China
- The First Affiliated Hospital of Dalian Medical University
-
-
Neimenggu
-
Baotou, Neimenggu, China
- Baotou City Central Hospital
-
Principal Investigator:
- Changchun Jiang
-
-
Shandong
-
Jining, Shandong, China
- Affiliated Hospital of Jining Medical University
-
Principal Investigator:
- Yongnan Hao
-
-
Yunnan
-
Kunming, Yunnan, China
- First Affiliated Hospital of Kunming Medical University
-
Principal Investigator:
- Chun Chen
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Hangzhou First People's Hospital
-
Principal Investigator:
- Congguo Yin
-
Ningbo, Zhejiang, China
- Ningbo First Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18-75
- Subjects with symptomatic intracranial atherosclerotic stenosis who do not respond to antiplatelet therapy or have poor compensation of collateral circulation and hypoperfusion in the offending vessel blood supply
- The last onset time of TIA is not limited or the last onset of ischemic stroke is more than 2 weeks
- The lesion is confirmed to be located in intracranial large arteries, including intracranial segment of the internal carotid artery, middle cerebral artery, intracranial segment of vertebral artery and the basilar artery
- Target vessel diameter≥2.0mm and ≤4.5mm, lesion length ≤33mm
- Stenosis degree of intracranial arteries≥70% and ≤99% measured by intracranial angiography (WASID method)
- Intracranial artery stenosis which requiring interventional treatment is a single lesion
- Subjects have at least 1 atherosclerotic plaque risk factor including hypertension, diabetes mellitus, hyperlipidemia, hyperhomocysteinemia, coronary heart disease, obesity, and smoking history
- mRS≤2 before enrollment
- Voluntarily participate in this study and sign the informed consent form, can complete examinations and follow-ups in accordance with the requirements of the protocol during the clinical trial
Exclusion Criteria:
- Intracranial arterial stenosis caused by non-atherosclerotic lesions: such as arterial dissection, moyamoya disease, vasculitis, active arteritis, etc.
- Preoperative MRI shows only perforator infarction in the target lesion
- Preoperative CT or MRI indicates the presence of post-infarct hemorrhagic transformation in the target vascular, or a history of subarachnoid, subdural, and epidural hemorrhage within 30 days before procedure, or the presence of untreated chronic subdural hematoma (≥5mm)
- Severe calcification of target vessels; or target vessel tortuosity or other reasons will make experimental device difficult to reach the target lesion position
- There is more than 70% stenosis in the distal intracranial large vessels or proximal intracranial and extracranial large vessels of the target vessels, and the presence of unidentified responsible lesions
- Subjects have a major surgery within 30 days before procedure or intend to be hospitalized for other procedure within 6 months after procedure
- Intracranial tumors or intracranial arteriovenous malformations, or distal and proximal target vessels combined with aneurysms
- The target lesion has a history of stent implantation
- It is suspected that there is severe allergy or contraindication to aspirin, clopidogrel, heparin, contrast media, nitinol and other drugs and devices related to endovascular therapy
- There is an underlying source of cardiac thrombus, such as atrial fibrillation, left ventricular thrombus, myocardial infarction within 30 days
- Subjects with an INR > 1.5 or the presence of nonmodifiable bleeding factors
- Medically uncontrolled severe hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg)
- Severe comorbid conditions or unstable conditions, such as severe heart failure, pulmonary failure, or renal failure (serum creatinine >3.0 mg/dL (264μmol/L)), severe liver insufficiency (ALT or AST >3 times normal), and malignancy
- Life expectancy is less than two years
- Women who are pregnant or breastfeeding
- Subjects unable to complete follow-up due to cognitive impairment, mood disorder, or mental illness
- Subjects who are enrolled in other clinical trials of drugs/devices and have not yet met the primary endpoint
- Other circumstances which investigators do not consider are appropriate for intracranial stent treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intracranial Stent (Tonbridge)
Placement of Intracranial Stent (Zhuhai Tonbridge Medical Tech.
Co., Ltd. ).
|
The intracranial stent consists of a self-expanding, laser-carved nickel-titanium stent and its delivery system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of in-stent restenosis at 6 months
Time Frame: 6 months post-procedure
|
The in-stent restenosis is defined as more than 50% stenosis within stent or distal/proximal ends (within 5 mm), and more than 20% absolute lumen loss.
The degree of intracranial artery stenosis are measured qualitatively in DSA examination.
WASID study will be used to measure the degree of intracranial artery stenosis.
|
6 months post-procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device success rate and procedural success rate
Time Frame: Intraoperation
|
Device success refers to the successful delivery of the stent to the lesion site through the delivery system during procedure, and it is released smoothly and fits well with the vessel wall without bending and displacement; procedural success is defined as stenosis degree less than 30% immediately after procedure.
|
Intraoperation
|
Incidence of symptomatic in-stent restenosis at 6 months, 1 year, and 2 years
Time Frame: 6 months, 1 year, and 2 years post-procedure
|
Symptomatic in-stent restenosis is defined as ischemic stroke or TIA or other ischemic neurological symptoms which are caused by in-stent restenosis.
|
6 months, 1 year, and 2 years post-procedure
|
Ratio of mRS 0-2 at 30 days, 6 months, 1 year, and 2 years
Time Frame: 30 days, 6 months, 1 year, and 2 years post-procedure
|
Subjects will be evaluated at the follow-up visits according to the mRS.
The mRS 0-2 indicates a good prognosis.
|
30 days, 6 months, 1 year, and 2 years post-procedure
|
Incidence of stent restenosis at 1 and 2 years
Time Frame: 1 and 2 years post-procedure
|
Restenosis is defined as more than 50% stenosis within stent or distal/proximal ends (within 5 mm), and more than 20% absolute lumen loss.
|
1 and 2 years post-procedure
|
Incidence of any stroke and death within 30 days
Time Frame: Within 30 days post-procedure
|
Stroke includes both ischemic and hemorrhagic strokes.
Deaths from any cause are included in this data.
|
Within 30 days post-procedure
|
Mortality at 31 days to 6 months, 6 to 12 months, and 12 to 24 months
Time Frame: 31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure
|
31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure
|
|
Incidence of ischemic stroke in the target vessel at 31 days to 6 months, 6 to 12 months, and 12 to 24 months
Time Frame: 31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure
|
31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure
|
|
Incidence of ischemic stroke in non-target vessel at 31 days to 6 months, 6 to 12 months, and 12 to 24 months
Time Frame: 31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure
|
31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure
|
|
The incidence of any hemorrhagic stroke at 31 days to 6 months, 6 to 12 months, and 12 to 24 months
Time Frame: 31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure
|
31 days to 6 months, 6 to 12 months, and 12 to 24 months post-procedure
|
|
Incidence of device deficiency
Time Frame: After use of device to end of study
|
Device deficiency is the unreasonable risk that may endanger human health or life safety in the normal use of medical devices during clinical trials, such as labeling errors, quality problems, malfunctions, etc. Possible device deficiency: labeling errors, product quality problems, design defects, broken sterilization packaging, etc.
|
After use of device to end of study
|
Incidence of adverse events (AE) at 30 days, 6 months, 1 year, and 2 years
Time Frame: Through 2 years post-procedure
|
Through 2 years post-procedure
|
|
Incidence of serious adverse events (SAE) at 30 days, 6 months, 1 year, and 2 years
Time Frame: Through 2 years post-procedure
|
Through 2 years post-procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Shouchun Wang, The First Hospital of Jilin University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 1, 2022
Primary Completion (Anticipated)
November 1, 2023
Study Completion (Anticipated)
May 1, 2025
Study Registration Dates
First Submitted
October 20, 2022
First Submitted That Met QC Criteria
October 20, 2022
First Posted (Actual)
October 25, 2022
Study Record Updates
Last Update Posted (Actual)
October 25, 2022
Last Update Submitted That Met QC Criteria
October 20, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZHTQ 202201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intracranial Atherosclerosis
-
Changhai HospitalNot yet recruitingICAS - Intracranial Atherosclerosis
-
Chinese PLA General HospitalRecruitingCerebral Small Vessel Diseases | ICAS - Intracranial AtherosclerosisChina
-
Chang Gung Memorial HospitalChang Gung UniversityRecruitingAcute Ischemic Stroke | Intracranial Atherosclerosis | ICAS - Intracranial AtherosclerosisTaiwan
-
Xiuhai GuoUnknownIntracranial AtherosclerosisChina
-
Wei-Hai XuPeking University First Hospital; General Hospital of Chinese Armed Police... and other collaboratorsUnknownAcute Ischemic Stroke AIS | Intracranial Atherosclerosis ICASChina
-
Yale UniversityRecruitingStroke | Intracranial AtherosclerosisUnited States
-
The 476th Hospital of People's Liberation ArmyUnknownIntracranial Atherosclerosis
-
Aga Khan UniversityCompletedIntracranial AtherosclerosisPakistan
-
Acotec Scientific Co., LtdBeijing Tiantan HospitalRecruitingStroke | Intracranial AtherosclerosisChina
-
Northwestern UniversityUniversity of ChicagoRecruiting
Clinical Trials on Intracranial Stent (Tonbridge)
-
Zhuhai Tonbridge Medical Tech. Co., Ltd.Not yet recruitingIntracranial AtherosclerosisChina
-
Zhuhai Tonbridge Medical Tech. Co., Ltd.Recruiting
-
Sinomed Neurovita Technology Inc.CompletedCerebrovascular Disorders | Brain Diseases | Ischemic Stroke, AcuteChina
-
Can Tho Stroke International Services HospitalAcandis GmbHRecruitingIschemic Stroke | Stent Stenosis | Intracranial AtherosclerosisVietnam
-
Medos International SARLRecruiting
-
MicroPort NeuroTech Co., Ltd.RecruitingBrain Diseases | Aneurysm | Intracranial AneurysmChina
-
MicroPort NeuroTech Co., Ltd.RecruitingCardiovascular Diseases | Brain Diseases | Aneurysm | Intracranial AneurysmChina
-
Sinomed Neurovita Technology Inc.Changhai HospitalActive, not recruitingIntracranial Arterial Diseases | Percutaneous Transluminal Angioplasty | Stent RestenosisChina
-
Zhejiang Zylox Medical Device Co., Ltd.Not yet recruitingAortic DissectionChina
-
NYU Langone HealthApproved for marketing